1. National Institute for Health and Clinical Excellence. Low dose rate brachytherapy for localised prostate cancer. Interventional Procedure Guidance 132. 2005
2. Kupelian PA, Potters L, Khuntia D et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2004; 58(1):25-33.
3. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localised prostate cancer. Annals of Internal Medicine 2008; 148(6): 435-48.
4. Colberg JW, Decker RH, Khan AM, et al. Surgery versus implant for early prostate cancer: results from a single institution, Cancer Journal 2007; 13 (4): 229-32.
5. Potters L, Klein E, Kattan M et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, permanent seed implantation. Radiotherapy & Oncology 2004; 71:29-33.
6. Bannuru RR, Dvorak T, Obadan N et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Annals of Internal Medicine 2011; 155 (3): 171-78.
7. Peinemann F, Grouven U, Hemkens LG et al. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database of Systematic Reviews 2011, Issue 7. Art No: CD008871.
8. Peinemann F, Grouven U, Bartel C et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. European Urology 2011: 60: 881-93.
9. National Institute for Health and Clinical Excellence. Prostate cancer. Diagnosis and treatment. NICE clinical guideline 58. 2008
10. Department of Health (2006). Advice on the development of low dose rate (permanent seed implant) brachytherapy services for localised prostate cancer in England. London: DoH; 2006
11. Michalski J, Mutic S, Eichling J et al. Radiation exposure to family and household members after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56(3):764-8.
12. Caloglu M & Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. Urology. 2009; 74(6):1183-90.
13. Langley SEM & Laing RW. Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer. Prostate Cancer & Prostatic Diseases 2004; 7:201-207.
14. Miller NL & Theodorescu D. Health-related quality of life after prostate brachytherapy. BJU International 2004; 94:487-491.
15. Heidenreich A, Bolla M, Joniau S et al. Guidelines on prostate cancer. European Association of Urology. 2012
16. Chen AB, D’Amico AV, Neville BA et al. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006;24(33):5298-304.
17. Royal College of Physicians. The effects of cancer treatments on reproductive functions. Guidance on Management. Report of a Working Party 2007. Available at: http://www.rcr.ac.uk/docs/oncology/pdf/Cancer_fertility_effects_Jan08.pdf
18. Boehmer D, Badakhshi H, Kuschke W et al. Testicular Dose in Prostate Cancer Radiotherapy: Impact on Impairment of Fertility and Hormonal Function. Strahlenther Onkol 2005: 181(3):179-84.
19. Khasksar SJ, Laing RW, & Langley SE. Fertility after prostate brachytherapy. BJU International 2005;96(6):915.
20. Bhatnagar V, Stewart ST, Huynh V et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer and Prostatic Diseases 2006; 1-11.
21. Phan J, Swanson DA, Levy LB et al. Late rectal complications after prostate brachytherapy for localised prostate cancer: incidence and management. Cancer 2009; 115 (9):1827-39.